Skip to main content
Muscles, Ligaments and Tendons Journal logoLink to Muscles, Ligaments and Tendons Journal
. 2015 Mar 27;5(1):1–4.

Reflections about the optimisation of the treatment of tendinopathies with PRP

Jean-François Kaux 1,2,3,, Marc Bouvard 4, Christelle Lecut 5, Cécile Oury 6, André Gothot 5, Mikel Sanchez 7, Jean-Michel Crielaard 1,2,3
PMCID: PMC4396669  PMID: 25878979

Summary

Background:

platelet-rich plasma (PRP) infiltration represents a recent therapy for chronic tendinopathies. However, in the literature, this treatment remains controversial.

Purpose:

we suggest some ideas for improving this treatment.

Methods:

these suggestions were based on a review of published studies and our clinical experience.

Conclusion:

optimizing the technique for PRP collection is paramount. Different risk factors must be corrected before infiltration and chronic tendinopathies must be carefully selected. Finally, post-infiltration rehabilitation remains absolutely critical. Standardization of the use of PRP remains necessary in order to optimize the results.

Keywords: platelet-rich plasma, PRP, rehabilitation, optimization

Introduction

Platelet-rich plasma (PRP) infiltration represents a recent therapy for chronic tendinopathies. Indeed, during degranulation, platelets release cytokines and growth factors (VEGF, PDGF, TGF-β, IGF-I, and HGF) that promote angiogenesis, tissue remodeling (bone, skin, muscle, tendon, etc.), and wound healing1. Most of the preclinical studies showed that PRP stimulates tendon healing process2. Thus, PRP could be an attractive therapeutic option for treating chronic musculoskeletal conditions, such as tendinopathy3. However, this treatment remains controversial4. Major difficulties in comparing and pooling clinical results stem from the fact that PRP is applied in different tendons (lateral epicondylitis, supraspinatus, patellar, Achilles…) and that outcome measurements vary between studies, even in those performed in the same tendon: e.g. epicondylitis, which is the most studied tendon, the variety of clinical scales makes comparisons difficult4,5. Based on the literature and our experience, we suggest some avenues for optimizing this treatment6.

Preparing PRP

Result variability may be explained by a misknowledge about PRPs7. Depending on how they are obtained and prepared, PRPs (or Platelet-Released Growth Factors PRGF) present highly variable concentrations of platelets810, erythrocytes and leukocytes. It is still necessary to optimize the techniques for obtaining and concentrating PRPs and standardizing the injection. Ideally, platelet concentration should be three to four times that of whole blood, i.e. between 600,000 and 900,000 platelets per microlitre1114; a concentration higher than 1,200,000 platelets may, indeed, be unfavorable14. Ideally, a reproducible PRP (with identical platelet concentration) should be injected to all patients. Currently, only platelet collection using an apheresis machine enables these objectives to be easily achieved15,16. The presence of white or red blood cells could be adverse to tissue healing process. It was demonstrated in vitro and animal studies that their absence limits the inflammatory response17. However, clinical positive effects of pure-PRP have not been demonstrated in controlled studies yet, and, in many clinical controlled studies, only a slight reduction of pain was obtained after a leukocyte rich-PRP injection. Moreover, it has been demonstrated that the anti-bacterial effect of PRP against Staphylococcus aureus, Staphylococcus epidermidis, Propionibacterium acnes and meticillin-resistant Staphylococcus aureus was not linked to the presence of leukocytes18.

Finally, platelet activation is reduced postprandially19. Moreover, a gentle mastication is able to induce the release of pro-inflammatory components into the bloodstream, especially when patients have severe periodontal disease20.

Thus, it would be preferable that patient should be fasting before preparing the PRP to reduce pro-inflammatory factors in platelet concentrate.

In addition, aspirin, corticosteroids and NSAIDs affect platelet functions and should be avoided at least during 10 days before blood collection2123.

Centrifugation speed should be set to a maximum of 900 rpm (100g), since a higher speed can lead to platelet activation and resulting decrease of platelet reactivity21,24.

After blood collection, it is mandatory to prepare the PRP as soon as possible (ideally within 1 hour) to avoid undesired non-specific platelet activation21,23,24. The PRP is stable for about 3 to 4 hours at room temperature, but platelets can become refractory to agonist stimulation21,23,24. Usually, citrate (or ACD-A) anticoagulation is highly recommended because it better preserves blood and ex vivo platelet reactivity. In contrast, EDTA and heparin should be avoided due to decreased platelet reactivity leading to reduced release of growth factors21,2326.

Correcting tendinopathy risk factors

Before planning any PRP infiltration, it is essential to undertake a precise diagnosis backed up by research and to correct any metabolic factors (diabetes, hyperuricemia, hypercholesterolemia, dysthyroidism)27. PRP effectiveness may be compromised by medications including quinolones, corticoides (orally or by infiltration), or statins27,28. These families of drugs accelerate tendon degeneration, which may lead to rupture28,29. Finally, sports technical mistakes and technopathies should also be corrected as well as a control of the physical stresses (sports or work).

Indications for PRP infiltration

Patients likely to benefit from PRP infiltration must be selected: relevant indications (but still debated in literature) relate to chronic corporeal tendinopathies (patellar, Achilles) which are resistant to conservative therapies (including prolonged eccentric rehabilitation and shock waves), without any osseous impingement or luxation30. It is imperative to surgically correct any osseous impingements (Haglund deformity, subacromial impingement and a Bigliani type III acromion, Sinding-Larsen-Johansson sequelae, etc.) before envisaging any further PRP infiltration30. Enthesopathies (epicondylitis, jumper’s knee, Achilles)may, in theory, benefit from PRP infiltration, although results remain less favourable, as with other treatments (such as shock waves), because of their particular histological structure30. For all inflammatory pathologies (e.g. enthesopathy in the context of a spondylarthropathy), it is crucial to treat the underlying inflammatory disease.

Therapeutic protocol

Although the product diffuses from the site of the injection31, it is best to conduct the infiltration in the tendon lesion using ultrasound, while respecting aseptic precautions32. A local anaesthetic is not recommended as it compromises the therapeutic potential of PRP: the anaesthetic may effectively reduce local pH, which is responsible for the inhibition and reduction or absence of platelet degranulation21,22,33. It was thus more recommended to use a small needle (30G) to decrease pain33. Although PRP is naturally activated upon contact with denatured collagen, platelet pre-activation (e.g. by CaCI2) promotes degranulation and thus the release of the growth factors involved in tissue healing13. A pH lower than than 7.7 inhibits platelet activation while a pH greater than 8.0 stimulates it. As the citrate used for the anticoagulation is slightly acidic, it is thus recommended to add a basic buffer like NaHCO3 before injection21.

After activation, 70% of the platelet growth factors are released from the α-granules within the first 10 minutes, and almost 100% have been secreted within the first hour34.

Even though there is no general agreement on the volume to be injected, 3 to 6 mL of PRP could be injected in the tendon, depending on its caliber. It could be interesting to determine whether the injected volume of PRP could influence the healing process based on the «degenerative state» of the tendon. Likewise, whether we should modify the protocol in case of enthesopathy or middle substance tendinopathy has never been investigated.

Post-infiltration consequences are often painful and may justify the use of local cryotherapy and analgesics. NSAIDs are to be avoided for 21 days following the procedure, as they may inhibit the PRP effect22,35. Once the algesic period has passed, progressively intensive sub-maximum eccentric rehabilitation, combined with stretching, will ‘guide’ tendon healing36. In animals, active mobilization of the infiltrated tendon improves tendon healing37; eccentric rehabilitation is more effective than concentric work38. For the first four to six weeks post-infiltration, rest from sport is necessary to avoid any new intra-tendinous lesions occurring; only rehabilitation, below the pain threshold, is permitted16. When sport is gradually resumed (reathletisation), any possible technique-related problems should be corrected and the tendon should be somewhat ‘protected’ using ‘functional’ orthoses (e.g. patellar brace) or ‘strapping’39.

In our series on the use of PRP to treat jumper’s knee, we have observed that younger patients respond more effectively to treatment, most probably because of their greater healing potential16,40. Those suffering from jumper’s knee for less than 10.5 months make the greatest progress40. Patients initially presenting with better quadricipital isocentric results during eccentric contraction at 30°/s and concentric contraction at 60°/s make better progress16. Moreover, patients presenting a significant reduction in pain after three months continue to progress positively up to one year later40. The three-month assessment looks at the effect of PRP infiltration and allows for a discussion to take place on the indication for a second PRP infiltration in the event of partial improvement to the tendinous symptoms41. Indeed, it was demonstrated that it was not useful to carry out 2 closely-timed infiltrations42. Surgery should be discussed in the absence of any improvement40.

In case of several applications, the refrigeration or lyophylisation of platelet could be performed43,44. However, after PRP freezing-thawing, platelets are lyzed and a platelet lysate is obtained44. It has been demonstrated that platelet lysate increase the growth rate of mesenchymal stem cells45.

Conclusion

PRP is a recent but controversial treatment for chronic tendinopathies. Standardization will be important to compare results and advance progress in the field, but it seems likely that more knowledge is awaited before proper standardization can be achieved. The first stage includes selecting the correct therapeutic indications and correcting the risk factors for tendinopathies. Subsequently, improving the techniques for obtaining PRP is crucial, as the injection protocol. Finally, post-infiltration rehabilitation remains absolutely necessary.

References

  • 1.Smets F, Croisier JL, Forthomme B, Crielaard JM, Kaux JF. Applications cliniques du Plasma riche en plaquettes (PRP) dans les lésions tendineuses: revue de la littérature. Science & Sport. 2012;27:141–153. [Google Scholar]
  • 2.Kaux JF, Drion PV, Colige A, Pascon F, Libertiaux V, Hoffmann A, et al. Effects of platelet-rich plasma (PRP) on the healing of Achilles tendons of rats. Wound Repair Regen. 2012;20:748–756. doi: 10.1111/j.1524-475X.2012.00826.x. [DOI] [PubMed] [Google Scholar]
  • 3.Kaux JF, Crielaard JM. Platelet-rich plasma application in the management of chronic tendinopathies. Acta Orthop Belg. 2013;79(1):10–15. [PubMed] [Google Scholar]
  • 4.Andia I, Latorre PM, Gomez MC, Burgos-Alonso N, Abate M, Maffulli N. Platelet-rich plasma in the conservative treatment of painful tendinopathy: a systematic review and meta-analysis of controlled studies. Br Med Bull. 2014;110(1):99–115. doi: 10.1093/bmb/ldu007. [DOI] [PubMed] [Google Scholar]
  • 5.de Vos RJ, Windt J, Weir A. Strong evidence against platelet-rich plasma injections for chronic lateral epicondylar tendinopathy: a systematic review. Br J Sports Med. 2014;48(12):952–956. doi: 10.1136/bjsports-2013-093281. [DOI] [PubMed] [Google Scholar]
  • 6.Padulo J, Oliva F, Frizziero A, Maffulli N. Muscles, Ligaments and Tendons Journal. Basic principles and recommendations in clinical and field science. MLTJ. 2013;4:250–252. [PMC free article] [PubMed] [Google Scholar]
  • 7.Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF) Trends Biotechnol. 2009;27(3):158–167. doi: 10.1016/j.tibtech.2008.11.009. [DOI] [PubMed] [Google Scholar]
  • 8.Kaux JF, Le Goff C, Seidel L, Peters P, Gothot A, Albert A, et al. Comparative study of five techniques of preparation of platelet-rich plasma. Pathol Biol (Paris) 2011;59(3):157–160. doi: 10.1016/j.patbio.2009.04.007. [DOI] [PubMed] [Google Scholar]
  • 9.Kaux JF, Le Goff C, Renouf J, Peters P, Lutteri L, Gothot A, et al. Comparison of the platelet concentrations obtained in platelet-rich plasma (PRP) between the GPS II and GPS III systems. Pathol Biol (Paris) 2011;59(5):275–277. doi: 10.1016/j.patbio.2010.11.002. [DOI] [PubMed] [Google Scholar]
  • 10.Malgoyre A, Bigard X, Alonso A, Sanchez MFK. Variabilité des compositions cellulaire et moléculaire des extraits de concentrés plaquettaires (platelet-rich plasma, PRP) Journal de Traumatologie du Sport. 2012;29:236–240. [Google Scholar]
  • 11.Weibrich G, Kleis WK, Hitzler WE, Hafner G. Comparison of the platelet concentrate collection system with the plasma-rich-in-growth-factors kit to produce platelet-rich plasma: a technical report. Int J Oral Maxillofac Implants. 2005;20(1):118–123. [PubMed] [Google Scholar]
  • 12.Anitua E. What is PRGF? In: Anitua E, editor. A biological approach to implantology. Vittoria; 2009. pp. 55–66. [Google Scholar]
  • 13.Lopez-Vidriero E, Goulding KA, Simon DA, Sanchez M, Johnson DH. The use of platelet-rich plasma in arthroscopy and sports medicine: optimizing the healing environment. Arthroscopy. 2010;26(2):269–278. doi: 10.1016/j.arthro.2009.11.015. [DOI] [PubMed] [Google Scholar]
  • 14.McCarrel TM, Minas T, Fortier LA. Optimization of leukocyte concentration in platelet-rich plasma for the treatment of tendinopathy. J Bone Joint Surg Am. 2012;94(19) doi: 10.2106/JBJS.L.00019. e143(1–8). [DOI] [PubMed] [Google Scholar]
  • 15.Moog R, Zeiler T, Heuft HG, Stephan B, Fischer EG, Kretschmer V, et al. Collection of WBC-reduced single-donor PLT concentrates with a new blood cell separator: results of a multicenter study. Transfusion. 2003;43(8):1107–1114. doi: 10.1046/j.1537-2995.2003.00467.x. [DOI] [PubMed] [Google Scholar]
  • 16.Kaux JF, Croisier JL, Bruyere O, et al. One injection of platelet-rich plasma associated to a submaximal eccentric protocol to treat chronic jumper’s knee. J Sports Med Phys Fitness. 2014 [PubMed] [Google Scholar]
  • 17.Anitua E, Sanchez M, Prado R, Orive G. The type of platelet-rich plasma may influence the safety of the approach. Knee Surg Sports Traumatol Arthrosc. 2012;22(7):1708–1709. doi: 10.1007/s00167-012-2043-1. [DOI] [PubMed] [Google Scholar]
  • 18.Intravia J, Allen DA, Durant TJ, McCarthy MB, Russell R, Beitzel K, et al. In vitro evaluation of the anti-bacterial effect of two preparations of platelet rich plasma compared with cefazolin and whole blood. Muscles, Ligaments and Tendons Journal. 2014;4(1):79–84. [PMC free article] [PubMed] [Google Scholar]
  • 19.Ahuja KD, Thomas GA, Adams MJ, Ball MJ. Postprandial platelet aggregation: effects of different meals and glycemic index. Eur J Clin Nutr. 2012;66(6):722–726. doi: 10.1038/ejcn.2012.28. [DOI] [PubMed] [Google Scholar]
  • 20.Geerts SO, Nys M, De MP, Charpentier J, Albert A, Legrand V, et al. Systemic release of endotoxins induced by gentle mastication: association with periodontitis severity. J Periodontol. 2002;73(1):73–78. doi: 10.1902/jop.2002.73.1.73. [DOI] [PubMed] [Google Scholar]
  • 21.Laffan M, Manning R. Investigation of haemostasis. In: Lewis SM, Brain BJ, Bates I, editors. Practical haematology. 10th ed. London: Churchill Livingstone; 2006. pp. 380–440. [Google Scholar]
  • 22.Foster TE, Puskas BL, Mandelbaum BR, Gerhardt MB, Rodeo SA. Platelet-rich plasma: from basic science to clinical applications. Am J Sports Med. 2009;37(11):2259–2272. doi: 10.1177/0363546509349921. [DOI] [PubMed] [Google Scholar]
  • 23.Harrison P, Mackie I, Mumford A, Briggs C, Liesner R, Winter M, et al. Guidelines for the laboratory investigation of heritable disorders of platelet function. Br J Haematol. 2011;155(1):30–44. doi: 10.1111/j.1365-2141.2011.08793.x. [DOI] [PubMed] [Google Scholar]
  • 24.Cattaneo M, Cerletti C, Harrison P, Hayward CP, Kenny D, Nugent D, et al. Recommendations for the Standardization of Light Transmission Aggregometry: A Consensus of the Working Party from the Platelet Physiology Subcommittee of SSC/ISTH. J Thromb Haemost. 2013 doi: 10.1111/jth.12231. [DOI] [PubMed] [Google Scholar]
  • 25.Born GV, Cross MJ. The Aggregation of Blood Platelets. J Physiol. 1963;168:178–195. doi: 10.1113/jphysiol.1963.sp007185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Greinacher A. Platelet activation by heparin. Blood. 2011;117(18):4686–4687. doi: 10.1182/blood-2011-03-341677. [DOI] [PubMed] [Google Scholar]
  • 27.Kaux JF, Forthomme B, Le Goff C, Crielaard JM, Croisier JL. Current opinion on tendinopathy. Journal of Sports Science and Medicine. 2011;10:238–253. [PMC free article] [PubMed] [Google Scholar]
  • 28.Kirchgesner T, Larbi A, Omoumi P, Malghem J, Zamali N, Manelfe J, et al. Drug-induced tendinopathy: From physiology to clinical applications. Joint Bone Spine. 2014 doi: 10.1016/j.jbspin.2014.03.022. [DOI] [PubMed] [Google Scholar]
  • 29.Chen SK, Lu CC, Chou PH, Guo LY, Wu WL. Patellar tendon ruptures in weight lifters after local steroid injections. Arch Orthop Trauma Surg. 2009;129(3):369–372. doi: 10.1007/s00402-008-0655-1. [DOI] [PubMed] [Google Scholar]
  • 30.Fichez O. Bonnes et mauvaises indications de l’injection de PRP dans les tendinopathies chroniques du sportif. In: Bard H, Bianchi S, Brasseur JL, Djian P, Guerini H, Lapègue F, et al., editors. Le tendon et son environnement. Sauramps Médical; 2013. pp. 243–252. [Google Scholar]
  • 31.Loftus ML, Endo Y, Adler RS. Retrospective analysis of postinjection ultrasound imaging after platelet-rich plasma or autologous blood: observational review of anatomic distribution of injected material. AJR Am J Roentgenol. 2012;199(4):W501–505. doi: 10.2214/AJR.11.8075. [DOI] [PubMed] [Google Scholar]
  • 32.Engebretsen L, Steffen K, Alsousou J, Anitua E, Bachl N, Devilee R, et al. IOC consensus paper on the use of platelet-rich plasma in sports medicine. Br J Sports Med. 2010;44(15):1072–1081. doi: 10.1136/bjsm.2010.079822. [DOI] [PubMed] [Google Scholar]
  • 33.Bausset O, Magalon J, Giraudo L, Louis ML, Serratrice N, Frere C, et al. Impact of local anaesthetics and needle calibres used for painless PRP injections on platelet functionality. Muscles, ligaments and tendons journal. 2014;4(1):18–23. [PMC free article] [PubMed] [Google Scholar]
  • 34.Marx RE. Platelet-rich plasma (PRP): what is PRP and what is not PRP? Implant Dent. 2001;10(4):225–228. doi: 10.1097/00008505-200110000-00002. [DOI] [PubMed] [Google Scholar]
  • 35.Nguyen RT, Borg-Stein J, McInnis K. Applications of platelet-rich plasma in musculoskeletal and sports medicine: an evidence-based approach. PM R. 2011;3(3):226–250. doi: 10.1016/j.pmrj.2010.11.007. [DOI] [PubMed] [Google Scholar]
  • 36.Kaux JF, Forthomme B, Namurois MH, Bauvir P, Defawe N, Delvaux F, et al. Description of a standardized rehabilitation program based on sub-maximal eccentric following a platelet-rich plasma infiltration for jumper’s knee. Muscles, Ligaments and Tendons Journal. 2014;4(1):85–89. [PMC free article] [PubMed] [Google Scholar]
  • 37.Virchenko O, Aspenberg P. How can one platelet injection after tendon injury lead to a stronger tendon after 4 weeks? Interplay between early regeneration and mechanical stimulation. Acta Orthop. 2006;77(5):806–812. doi: 10.1080/17453670610013033. [DOI] [PubMed] [Google Scholar]
  • 38.Kaux JF, Drion P, Libertiaux V, Colige A, Hoffmann A, Nusgens B, et al. Eccentric training improves tendon biomechanical properties: a rat model. J Orthop Res. 2013;31(1):119–124. doi: 10.1002/jor.22202. [DOI] [PubMed] [Google Scholar]
  • 39.Clifford AM, Harrington E. The effect of patellar taping on squat depth and the perception of pain in people with anterior knee pain. Journal of human kinetics. 2013;37:109–117. doi: 10.2478/hukin-2013-0031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Kaux JF, Bruyere O, Croisier JL, et al. One-year follow-up of platelet-rich plasma infiltration to treat chronic upper patellar tendinopathies. Acta Orthop Belg. In Press. [PubMed] [Google Scholar]
  • 41.Dallaudiere B, Meyer P, Hummel V, Perozziello A, Peuchant A, Moreau-Durieux MH, et al. Efficacy of second intra-tendinous platelet-rich-plasma injection in case of incomplete response of the first injection: three-year follow up experience. Diagnostic and interventional imaging. 2013;94(9):871–877. doi: 10.1016/j.diii.2013.05.010. [DOI] [PubMed] [Google Scholar]
  • 42.Kaux JF, Croisier JL, Forthomme B, et al. Using platelet-rich plasma to treat jumper’s knees: exploring the effects of a second closely-timed infiltration. J Sci Med Sport. In Press. [DOI] [PubMed]
  • 43.Cap AP, Perkins JG. Lyophilized platelets: challenges and opportunities. J Trauma. 2011;70(5 Suppl):S59–60. doi: 10.1097/TA.0b013e31821a606d. [DOI] [PubMed] [Google Scholar]
  • 44.Jonsdottir-Buch SM, Lieder R, Sigurjonsson OE. Platelet lysates produced from expired platelet concentrates support growth and osteogenic differentiation of mesenchymal stem cells. PLoS One. 2013;8(7):e68984. doi: 10.1371/journal.pone.0068984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Ben Azouna N, Jenhani F, Regaeya Z, Berraeis L, Ben Othman T, Ducrocq E, et al. Phenotypical and functional characteristics of mesenchymal stem cells from bone marrow: comparison of culture using different media supplemented with human platelet lysate or fetal bovine serum. Stem cell research & therapy. 2012;3(1):6. doi: 10.1186/scrt97. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Muscles, Ligaments and Tendons Journal are provided here courtesy of CIC Edizioni Internazionali

RESOURCES